Looks like you’re on the US site. Choose another location to see content specific to your location

Geron Gain FDA Approval for Blood Cancer Treatment
After a 33-year journey, Geron was finally granted FDA clearance. The infused medication Rytelo has been approved by the government for the therapy of a class of bone marrow malignancy illnesses known as myelodysplastic syndromes (MDS).
“The (approval) is a testament to the power of our science, the excellence of our clinical and regulatory execution and the authentic passion of our people to innovate treatment for patients in need,” John Scarlett, Geron’s CEO, stated.
Following the approval, Geron’s stock price surged by 22%. The business became public in 1996.
Geron’s will evaluate its capacity to bring its initial treatment to the market. To assist in promoting the medication in the United States, the business hired a number of seasoned executives last year, notably Lorraine Shui, a former vice president of marketing at Novartis, and Scott Hutson, a former vice president of sales at AstraZeneca.
We have hundreds of jobs available across the Healthcare industry, find your perfect one now.
- Share Article
- Share on Twitter
- Share on Facebook
- Share on LinkedIn
- Copy link Copied to clipboard